Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study by Gattorno, M et al.
EXTENDED REPORT
Canakinumab treatment for patients with active
recurrent or chronic TNF receptor-associated periodic
syndrome (TRAPS): an open-label, phase II study
Marco Gattorno,1 Laura Obici,2 Marco Cattalini,3 Vincent Tormey,4 Ken Abrams,5
Nicole Davis,5 Antonio Speziale,6 Suraj G Bhansali,5 Alberto Martini,1,7
Helen J Lachmann8
Handling editor Tore K Kvien
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
annrheumdis-2015-209031).
For numbered afﬁliations see
end of article.
Correspondence to
Dr Marco Gattorno, UO
Pediatria 2, Istituto G. Gaslini,
Via G. Gaslini 5, Genova
16147, Italy; marcogattorno@
ospedale-gaslini.ge.it
Received 15 December 2015
Revised 27 April 2016
Accepted 17 May 2016
To cite: Gattorno M,
Obici L, Cattalini M, et al.
Ann Rheum Dis Published
Online First: [please include
Day Month Year]
doi:10.1136/annrheumdis-
2015-209031
ABSTRACT
Objective To evaluate the efﬁcacy of canakinumab, a
high-afﬁnity human monoclonal anti-interleukin-1β
antibody, in inducing complete or almost complete
responses in patients with active tumour necrosis factor
receptor-associated periodic syndrome (TRAPS).
Methods Twenty patients (aged 7–78 years) with
active recurrent or chronic TRAPS were treated with
canakinumab 150 mg every 4 weeks for 4 months
(2 mg/kg for those ≤40 kg) in this open-label, proof-of-
concept, phase II study. Canakinumab was then
withdrawn for up to 5 months, with reintroduction on
relapse, and 4 weekly administration (subsequently
increased to every 8 weeks) for 24 months. The primary
efﬁcacy variable was the proportion of patients achieving
complete or almost complete response at day 15,
deﬁned as clinical remission (Physician’s Global
Assessment score ≤1) and full or partial serological
remission.
Results Nineteen patients (19/20, 95%; 95% CI
75.1% to 99.9%) achieved the primary efﬁcacy variable.
Responses to canakinumab occurred rapidly; median
time to clinical remission 4 days (95% CI 3 to 8 days).
All patients relapsed after canakinumab was withdrawn;
median time to relapse 91.5 days (95% CI 65 to
117 days). On reintroduction of canakinumab, clinical
and serological responses were similar to those seen
during the ﬁrst phase, and were sustained throughout
treatment. Canakinumab was well tolerated and clinical
responses were accompanied by rapid and sustained
improvement in health-related quality of life. Weight
normalised pharmacokinetics of canakinumab, although
limited, appeared to be consistent with historical
canakinumab data.
Conclusions Canakinumab induces rapid disease
control in patients with active TRAPS, and clinical
beneﬁts are sustained during long-term treatment.
Trial registration number NCT01242813; Results.
INTRODUCTION
Tumour necrosis factor (TNF) receptor-associated
periodic syndrome (TRAPS) is an autosomal-
dominant autoinﬂammatory disorder resulting
from variants in the TNF super family receptor 1A
(TNFRSF1A) gene.1 Clinically, TRAPS is charac-
terised by recurrent fever, myalgia, abdominal pain,
rash, headaches, ocular symptoms and in some
cases, amyloid A (AA) amyloidosis.2 3 Diagnosis is
challenging due to the considerable genetic hetero-
geneity and variable clinical presentation.4
Non-steroidal anti-inﬂammatory drugs (NSAIDs)
can relieve fever but have little other beneﬁt in
TRAPS, and conventional immunomodulators are
ineffective.2 Biologics that target speciﬁc proinﬂam-
matory cytokines have been investigated as treat-
ment for TRAPS. At the time of the identiﬁcation
of the molecular defect, the TNF inhibitor etaner-
cept was the cornerstone of TRAPS therapy1; it
attenuates symptoms and inﬂammatory markers but
many patients discontinue therapy due to perceived
lack of efﬁcacy.5–7 Paradoxically, treatment with the
TNF inhibitors inﬂiximab and adalimumab can
precipitate inﬂammatory attacks and disease worse-
ning.8–10
TNFRSF1A gene mutations in TRAPS are
thought to cause aberrant trafﬁcking and localisa-
tion of the type I TNF receptor, resulting in intra-
cellular stress ultimately leading to increased
production of interleukin-1β (IL-1β).11 12 While
the pathogenesis of TRAPS is complex and still not
completely understood, patients with TRAPS have
excellent short-term response to the IL-1 receptor
antagonist anakinra, suggesting IL-1β as a rational
therapeutic target.7 13 14
Canakinumab is a high-afﬁnity human monoclo-
nal IL-1β antibody of the IgG1/κ isotype that binds
to IL-1β, thereby blocking the interaction of
the cytokine with its receptor.15 16 Case studies
have demonstrated that patients with TRAPS can
achieve a complete or near complete response with
canakinumab treatment.17 18 This phase II proof-
of-concept study was designed to evaluate the
efﬁcacy and safety of canakinumab in inducing
complete or almost complete responses within
15 days after the ﬁrst dose in patients with active
TRAPS.
METHODS
Study design
This open-label, single-treatment arm, proof-of-
concept, phase II study was conducted at six centres
(four in Italy, one in England and one in Ireland)
from 2010 to 2014. The study was registered at
ClinicalTrials.gov (NCT01242813), and was con-
ducted according to the ethical principles from the
Declaration of Helsinki and in compliance with
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Good Clinical Practice. An independent ethics committee at each
site approved the protocol.
The study enrolled patients with a clinical diagnosis of active
recurrent or chronic TRAPS with a conﬁrmed mutation of the
TNFRSF1A gene (see online supplement for eligibility criteria),
and consisted of a 4-month treatment period, followed by a
withdrawal/follow-up period lasting up to 5 months, and, on
disease relapse, a 24-month long-term treatment period (see
online supplementary ﬁgure S1). Patients weighing >40 kg
received canakinumab 150 mg subcutaneously once every four
weeks during the treatment period (days 1, 29, 57 and 85). A
single-dose up-titration to 300 mg was permitted at day 8 in
non-responders at the discretion of the treating physician.
Patients weighing ≤40 kg received canakinumab 2 mg/kg once
every four weeks, with a single-dose up-titration to 4 mg/kg
allowed for non-responders at day 8. Patients who relapsed
during the follow-up period received another dose of canakinu-
mab equivalent to the last dose received, and then returned
2 weeks later for the end of follow-up visit. All patients who
completed or relapsed during the follow-up period entered the
long-term treatment period. In patients with a stable complete
response, corticosteroid doses could be reduced at the investiga-
tors discretion from day 29 for complete responders only. The
once every four weeks dosing regimen was chosen in the absence
of sufﬁcient clinical pharmacokinetic/pharmacodynamic data
in patients with TRAPS. However, in the long-term treatment
period, based on obtained pharmacokinetic/pharmacodynamic
data, patients were transitioned to a dosing interval of once
every eight weeks.
Efﬁcacy, pharmacokinetic and safety assessments
Patients had visits on days 1 (baseline), 3, 8, 15, 29, 57 and 85,
and then every 4 weeks during follow-up and long-term treat-
ment. At each visit, investigators completed a global assessment
using a 5-point Physician’s Global Assessment (PGA) scale with
scores of 0 (none), 1 (minimal), 2 (mild), 3 (moderate) and 4
(severe) for TRAPS-associated clinical signs and symptoms. The
PGA was developed based upon discussions with the principal
investigators and in accordance with the same instrument used
previously in canakinumab trials in CAPS;19 the PGA was not
validated for use in TRAPS. Investigators also rated the severity
of four-key associated signs and symptoms (rash, extremity mus-
culoskeletal pain, abdominal pain and eye manifestations) using
a 5-point scale with scores of 0 (absent), 1 (minimal), 2 (mild),
3 (moderate) and 4 (severe). Fever (>38.5°C) was also assessed
at all visits. The inﬂammatory markers C-reactive protein (CRP)
and serum amyloid A (SAA) were measured at each visit; CRP
levels were determined locally and standardised to a normal
range of 0–10 mg/L, and SAA levels were determined at the
central laboratory.
The primary efﬁcacy variable was the proportion of patients
with active TRAPS achieving complete or almost complete
response at day 15. Complete response was deﬁned as clinical
remission (PGA score ≤1) with full serological remission (CRP
<10 mg/L and/or SAA <10 mg/L), and almost complete
response was deﬁned as clinical remission with partial sero-
logical remission (≥70% reduction of baseline CRP and/or
SAA). Non-response was deﬁned as no change or worsening
from baseline PGA score and/or increased or <50% reduction
from baseline CRP and/or SAA. Clinical relapse was deﬁned by
an increase in PGA score of ≥1 point from day 15 to a PGA
score ≥2, and serological relapse was deﬁned by an increase in
CRP and/or SAA by 30% from day 15 to a value ≥30 mg/L
unless it resulted from other factors (eg, concurrent infection).
Secondary efﬁcacy variables included the proportion of patients
with complete or almost complete response at day 8, the pro-
portion with clinical remission at days 8 and 15, the proportion
with serological remission at days 8 and 15, the time to the
investigator’s assessment of clinical remission, and the time to
relapse in the withdrawal phase. The designation of almost com-
plete response was made to identify patients with evident ameli-
oration of disease activity, and functionally served to select
patients who did not need re-dosing with canakinumab.
Pharmacokinetic and safety assessments are described in the
online supplement.
Health-related quality of life
Exploratory objectives included an assessment of long-term
maintenance of disability and health-related quality of life
(HRQoL) of canakinumab treatment in patients with TRAPS.
Patients completed HRQoL questionnaires on days 1, 15, 113,
253 and then every 12 weeks during long-term treatment.
Patients ≥18 years of age at baseline completed the Medical
Outcomes Study 36-Item Short Form Health Survey (SF-36),
and those <18 years completed the Child Health Questionnaire
(CHQ-PF50). Neither of these tools has been validated for use
in TRAPS.
RESULTS
Patients
Twenty patients were treated with canakinumab and all entered
the long-term treatment period. Eighteen patients completed
the long-term treatment period. Two patients were lost to
follow-up after receiving treatment to days 673 and 692,
respectively. The mean age of the study cohort was 34.6 years;
95% were white and 65% were male (table 1). Six patients were
<18 years of age (paediatric) and 14 patients were ≥18 years of
age (adult). The mean duration of time since TRAPS diagnosis
at entry was 4.6 years. Nine patients had recurrent TRAPS, with
a mean of 9.9±2.32 episodes per year and episodes lasting for a
mean of 11.9±3.76 days. The remaining 11 patients had
chronic TRAPS, with continuous symptoms or persistent eleva-
tion of acute phase reactants; one of those patients required
continuous steroid treatment. Three patients (15%) had AA
amyloidosis, one of these also had a medical history of bronchi-
ectasis and retroperitoneal ﬁbrosis. Overall, 19 patients (95%)
received prior TRAPS treatment (table 1), which was discontin-
ued per the protocol. Canakinumab was initiated when patients
met criteria for active TRAPS but before they developed a severe
disease ﬂare.
Efﬁcacy
The primary efﬁcacy endpoint of complete or almost complete
response at day 15 was achieved by 19 of 20 patients (95%;
95% CI 75.1% to 99.9%). The other patient had achieved a
complete response at day 8, but lost the serological response at
day 15 despite ongoing clinical remission. Overall, 16 patients
(80%) achieved a complete response at day 8, and 2 additional
patients (n=18; 90%) experienced complete clinical remission
(ie, PGA score ≤1) at day 8 despite not yet achieving a sero-
logical response (ﬁgure 1). All patients remained in clinical
remission during the 4-month treatment period except for one
patient who had a PGA assessment of mild TRAPS activity at
the day 85 dosing visit. The median time to clinical remission
was 4 days (95% CI 3 to 8 days) (see online supplementary
ﬁgure S2). Canakinumab improved each of the key signs and
symptoms of TRAPS (see online supplementary table S1). The
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six paediatric patients responded similarly to the adults, with all
achieving a complete or almost complete response at day 15.
The inﬂammatory biomarkers CRP and SAA decreased
rapidly after initiation of canakinumab treatment. Both CRP and
SAA were within normal ranges (≤10 mg/L) in seven patients
(35%) on day 8 and in 12 patients (60%) on day 15. For the
study cohort, median CRP and SAA declined to ≤10 mg/L by
day 15 and remained within a normal range for the duration of
the treatment period (ﬁgure 2). Median CRP and SAA values
were 4.8 and 2.2 mg/L, respectively, at the end of the treatment
period, and remained within the normal range throughout the
long-term treatment period (see online supplementary table S2).
At the end of study visit, median CRP and SAA levels were 4.0
and 4.85 mg/L, respectively.
Up-titration was allowed for patients who did not achieve a
complete or almost complete response at day 8. Two of the four
non-responders at day 8 were up-titrated and achieved a com-
plete or almost complete response by day 15. Despite not
receiving up-titration the other two patients still achieved a
complete or almost complete response at day 15.
All 20 patients relapsed (11 mild, 7 moderate and 2 severe)
during the canakinumab withdrawal/follow-up period. Based on
Kaplan-Meier estimates, the median time to relapse following
the last canakinumab dose was 91.5 days (95% CI 65 to
117 days) (see online supplementary ﬁgure S3). At 2 weeks after
re-starting canakinumab following relapse, all patients returned
to the level of response they had achieved prior to stopping
canakinumab.
Based on analysis of time to relapse, the pharmacokinetic data
obtained, and the desire of both patients and physicians to
decrease the dose frequency, all patients in the long-term treat-
ment period transitioned to a maintenance dosing interval of
once every eight weeks of the last dose they received on day 85
(ie, 150 or 300 mg (or 2 or 4 mg/kg, respectively, if <40 kg)).
For seven patients (35%; six adults, one child), the decreased
dosing frequency at the lower 150-mg dose was not adequate to
maintain disease control: three patients experienced one relapse
episode, three patients experienced two relapse episodes and
one patient experienced ﬁve relapse episodes. Four patients
received NSAIDs and one patient received corticosteroid
Table 1 Baseline demographics and disease characteristics
Characteristic Study cohort (N=20)
Age, years
Mean (SD) 34.6 (18.36)
Range 7.0–77.8
Age range, years
<18 6 (30)
≥18 14 (70)
Sex, n (%)
Male 13 (65)
Female 7 (35)
Race, n (%)
White 19 (95)
Asian 1 (5)
Duration since TRAPS diagnosis, years
Mean (SD) 4.6 (3.57)
Range 0.01–11.7
Mutation of TNFRSF1A gene, n (%) 20 (100)
T50M 4 (20)
C55Y 2 (10)
C33Y 2 (10)
C72N 2 (10)
C29Y 1 (5)
C52Y 1 (5)
D42del 1 (5)
C30R 1 (5)
T371 1 (5)
F60L 1 (5)
Y38S 1 (5)
C43G 1 (5)
C72Y 1 (5)
C81Y 1 (5)
Diagnosis of TRAPS, n (%)
Chronic 11 (55)
Relapsing 9 (45)
Number of episodes/year: mean (SD) 9.9 (2.32)
Duration of each episode, days: mean (SD) 11.9 (3.76)
CRP, mg/L: median (range) 125 (6–564)
SAA, mg/L: median (range) 198 (16–2270)
PGA of TRAPS activity, n (%)
2 (mild) 13 (65)
3 (moderate) 6 (30)
4 (severe) 1 (5)
Disease-related medication taken before but stopped prior to study entry,* n (%)
IL-1 inhibitor (anakinra) 13 (65)†
TNF inhibitor (etanercept) 6 (30)‡
Glucocorticoids 10 (50)§
NSAIDs 3 (15)¶
*As per study protocol.
†CR, n=12; PR, n=1.
‡CR, n=3; PR, n=3.
§CR, n=6; PR, n=2; other, n=2 (treatment of TRAPS attack, prophylaxis).
¶PR, n=3.
CR, complete response; CRP, C-reactive protein (standardised); IL, interleukin; NSAID,
non-steroidal anti-inflammatory drug; PGA, Physician’s Global Assessment; PR, partial
response; SAA, serum amyloid A; TNF, tumour necrosis factor; TRAPS, TNF
receptor-associated periodic syndrome.
Figure 1 Distribution of Physician’s Global Assessment (PGA) scores
at various study visits. Clinical remission=PGA ≤1. *Eighteen patients
remained in the study until the end.
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treatment to manage these acute relapses. The dose of canakinu-
mab was up-titrated to 300 mg once every eight weeks in ﬁve of
these patients, while the dose was not up-titrated in the remain-
ing two patients, as they had isolated relapses not deemed
severe or frequent enough by their treating physician to warrant
a dose escalation.
Health-related quality of life
At baseline, 16 patients completed the SF-36 at least once. The
patients exhibited considerable deﬁcits in HRQoL compared
with age and gender matched norms across all SF-36 domains;
the mean differences on all domains exceeded the minimal clin-
ically important difference of each scale and were statistically
signiﬁcant (p<0.05). The greatest deﬁcits in terms of effect
sizes between patients with TRAPS and the general US popula-
tion were observed for the role emotional, general health and
bodily pain domains (ﬁgure 3A). When compared with bench-
mark samples of patients with other diseases, the HRQoL of the
patients with TRAPS was most closely matched to patients with
rheumatoid arthritis. Domain and summary SF-36 scores for the
patients with TRAPS were consistently below those for patients
with osteoarthritis or chronic back problems.
Treatment with canakinumab rapidly improved HRQoL in
parallel with clinical improvement (ﬁgure 3B). Scores on all
SF-36 domains increased from baseline to day 15 (n=14), with
mean scores >50 (general population average) on the physical
functioning and vitality domains. By the end of treatment
period on day 113 (n=15), all domain scores were >50 except
for general health and role emotional. The mean physical com-
ponent summary score improved from 41.8 at baseline to 49.3
at day 15 and 51.4 at day 113; the mean mental component
summary score showed improvements from 39.3 at baseline to
46.6 at day 15 and 49.0 at day 113. For the ﬁve paediatric
patients who completed the CHQ-PF50 questionnaire, the mean
physical health and psychosocial scores at baseline were 35.4 and
52.7, respectively. Improvements in mean physical health scores
to >40 were evident by day 15 and were maintained at the end
of treatment and end of follow-up visits. Mean psychosocial
scores remained >50 throughout the study, except on days 365
and 617, they were noted at 46.6 and 47.2, respectively.
Pharmacokinetic proﬁle
In general, canakinumab displayed pharmacokinetic properties
typical of an IgG1 monoclonal antibody. The pharmacokinetics of
canakinumab in this population were consistent with that observed
in other disease populations (see online supplementary table S3).
Safety
Canakinumab treatment was well tolerated; all patients reported
at least one adverse event (AE), most commonly nasopharyngi-
tis, abdominal pain, headache and oropharyngeal pain (table 2).
Most AEs were mild to moderate in severity, and none led
to study discontinuation. Serious adverse events, including peri-
carditis, abdominal pain, diarrhoea, intestinal obstruction,
vomiting, upper respiratory tract infection, meniscus injury,
hypertriglyceridaemia, hyperkalemia, pregnancy-related condi-
tion (ie, wife of enrolled patient became pregnant), foot deform-
ity and condition aggravated occurred in seven patients. None
of these events were suspected as drug-related study (see online
supplementary table S4). There were no meaningful changes
in haematology, clinical chemistry or vital signs during the
study, and no neutralising anti-canakinumab antibodies were
identiﬁed.
DISCUSSION
Canakinumab treatment produced rapid clinical and sero-
logical responses in paediatric and adult patients with active
TRAPS. All patients achieved clinical remission in a median of
4 days after the ﬁrst canakinumab dose. Importantly, both
Figure 2 Median C-reactive protein (CRP) and serum amyloid A
(SAA) values during the 4-month treatment period in the study cohort.
BL, baseline; ULN, upper limit of normal.
Figure 3 SF-36 spydergrams. (A) Comparison of tumour necrosis factor receptor-associated periodic syndrome (TRAPS) cohort with age and gender
matched US population norm. (B) Effect of canakinumab at day 15 (primary endpoint) and day 113 (end of treatment period) compared with
baseline.
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median CRP and SAA declined into the normal range by day
15. The remarkable clinical and serological response was paral-
leled by a similarly rapid and robust improvement in HRQoL.
Responses were sustained with continued canakinumab dosing;
relapse occurred in all patients after withdrawal of canakinu-
mab, but responses were restored after restarting canakinumab
treatment.
This study corroborates ﬁndings from previous anecdotal
reports in which the IL-1 receptor antagonists anakinra14 20 and
canakinumab18 were used in the treatment of patients with
refractory TRAPS, and support the key role of IL-1β rather than
TNF in the pathogenesis of TRAPS. Clinically, TNF inhibition
with etanercept, has proved disappointing in TRAPS.1 21 In the
only prospective, open-label study, the beneﬁt of etanercept was
not sustained over time and 8 of 14 patients discontinued eta-
nercept in the ﬁrst 2 years, mainly due to lack of efﬁcacy.5
Prior to our study, 65% of the patients had been treated suc-
cessfully with the IL-1 receptor antagonist anakinra, and after a
brief washout period, all responded to canakinumab, further
supporting the long-term efﬁcacy of IL-1 inhibition compared
with TNF inhibition in patients with TRAPS.7
For the long-term period, patients were transitioned from
canakinumab once every four weeks to once every eight weeks,
the same dosing interval indicated for patients with another
hereditary fever syndrome, cryopyrin-associated periodic syn-
dromes.15 However, because maintenance canakinumab at
150 mg once every eight weeks led to relapses in a signiﬁcant
minority (35%) of patients, a 150-mg once every four weeks
regimen has been adopted for the ongoing pivotal phase III clin-
ical trial (clinicaltrials.gov NCT02059291) evaluating efﬁcacy
and safety of canakinumab versus placebo in patients with her-
editary periodic fever syndromes (TRAPS, familial
Mediterranean fever and hyperimmunoglobulin D syndrome/
mevalonate kinase deﬁciency).22
At baseline, patients with TRAPS showed a clinically meaning-
ful and statistically signiﬁcant decrement in HRQoL compared
with age and gender matched US population norms. Mean phys-
ical and mental component summary scores as well as 5 domain
scores in the TRAPS cohort were 10 points below those for
the US population (ie, 2 SDs lower). Notably, treatment with
canakinumab rapidly improved HRQoL, with SF-36 component
and domain scores approaching or reaching those for the
normal US population.
In general, canakinumab displayed pharmacokinetic proper-
ties typical of an IgG1 monoclonal antibody with ﬁndings in
this population consistent with that observed in other disease
populations.
The benign safety proﬁle observed in this small study was con-
sistent with that observed in larger blinded trials of canakinumab
in other conditions, including CAPS and systemic idiopathic
juvenile arthritis.23 24 The oldest patient treated in this study was
77 years old with comorbidities, and she has been treated suc-
cessfully for several years without serious adverse events.
In summary, this study demonstrates that canakinumab pro-
duces rapid and robust clinical and serological responses, with
parallel improvements in HRQoL, in patients with active
TRAPS. This study supports continued exploration of the use of
canakinumab in the treatment of TRAPS.
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Table 2 Adverse events occurring in at least 3 patients by preferred
term during the entire study (study duration: 33 months)
Adverse event, n (%) Study cohort (N=20)
Any adverse event 20 (100)
Nasopharyngitis 12 (60)
Abdominal pain 11 (55)
Headache 11 (55)
Oropharyngeal pain 11 (55)
Fever 10 (50)
Diarrhoea 9 (45)
Arthralgia 8 (40)
Vomiting 8 (40)
Fatigue 7 (35)
Upper respiratory tract infection 7 (35)
Cough 6 (30)
Musculoskeletal pain 6 (30)
Myalgia 6 (30)
Dizziness 5 (25)
Rhinitis 5 (25)
Abdominal pain upper 4 (20)
Bronchitis 4 (20)
Condition aggravated 4 (20)
Pharyngitis 4 (20)
Back pain 3 (15)
Chest pain* 3 (15)
Cystitis 3 (15)
Ear pain 3 (15)
Epistaxis 3 (15)
Lower respiratory tract infection 3 (15)
Pain in extremity 3 (15)
Paraesthesia 3 (15)
Rash 3 (15)
Respiratory tract infection 3 (15)
Toothache 3 (15)
Viral infection 3 (15)
*Of these three events, two were non-cardiac chest pain and the other was related to
tumour necrosis factor receptor-associated periodic syndrome (TRAPS) disease activity.
None were considered related to canakinumab by the investigator.
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